CD58在儿童急性B淋巴细胞白血病中的表达及其用于微小残留病检测的可行性研究

李亚飞; 赵晓明; 盛光耀; 岳保红; 罗源

doi:10.7499/j.issn.1008-8830.2015.08.013

PDF(1435 KB)

HTML

中国当代儿科杂志 ›› 2015, Vol. 17 ›› Issue (8) : 825-829. DOI: 10.7499/j.issn.1008-8830.2015.08.013

论著·临床研究

CD58在儿童急性B淋巴细胞白血病中的表达及其用于微小残留病检测的可行性研究

李亚飞, 赵晓明, 盛光耀, 岳保红, 罗源

作者信息 +

Expression of CD58 in childhood B-lineage acute lymphoblastic leukemia and its feasibility in minimal residual disease detection

LI Ya-Fei, ZHAO Xiao-Ming, SHENG Guang-Yao, YUE Bao-Hong, LUO Yuan

Author information +

文章历史 +

摘要

目的检测淋巴细胞功能相关抗原-3(CD58)在儿童急性B淋巴细胞白血病(B-ALL)中的表达情况,并探讨其用于儿童B-ALL微小残留病(MRD)检测的可行性。方法选取2014年1~9月确诊为B-ALL的87例患儿为研究对象,同期选取20例非肿瘤、非血液病且骨髓涂片细胞形态正常的住院患儿作为对照组。应用四色流式细胞术(FCM)检测对照组及B-ALL患儿初诊时、诱导化疗15 d时骨髓标本的CD58表达水平。在诱导化疗33 d时,采用实时荧光定量聚合酶链反应(RT-PCR)和FCM对B-ALL患儿进行MRD检测。结果 87例B-ALL患儿骨髓CD58平均荧光强度(MFI)(91±33)高于对照组(14±6)(P< 0.01);其中44例B-ALL患儿CD58强表达。在诱导化疗过程中,诱导化疗15 d时B-ALL患儿骨髓CD58的表达量(105±22)与初诊时(107±26)比较差异无统计学意义(P> 0.05)。对44例CD58强表达B-ALL患儿进行MRD检测,FCM检测MRD阳性患儿9例,阴性患儿35例;RT-PCR检测MRD阳性患儿11例,阴性患儿33例,42例(95%)检测结果一致,两种检测方法检测MRD差异无统计学意义(P> 0.05)。结论 CD58在B-ALL患儿中高表达且表达稳定,可以作为B-ALL患儿MRD检测的指标。

Abstract

Objective To measure the expression of lymphocyte function-associated antigen-3 (CD58) in childhood B-lineage acute lymphoblastic leukemia (B-ALL) and to explore the feasibility of CD58 as an indicator for minimal residual disease (MRD) detection in childhood B-ALL. Methods Eighty-seven children diagnosed with B-ALL between January 2014 and September 2014 were enrolled, and 20 hospitalized children who had no tumor or blood disease and had normal bone marrow cell morphology served as the control group. The expression features of CD58 in bone marrow samples from the two groups (at diagnosis, on day 15 of induction chemotherapy) were analyzed by four-color flow cytometry (FCM). Quantitative real-time polymerase chain reaction (qRT-PCR) and FCM were used to detect MRD in B-ALL patients on day 33 of induction chemotherapy. Results The mean fluorescence intensity of CD58 expression in the 87 B-ALL cases (91±33) was significantly higher than that in the 20 controls (14±6) (P< 0.01); CD58 was over-expressed in 44 of the B-ALL cases. In the B-ALL children, the expression of CD58 on day 15 of induction chemotherapy (105±22) was not significantly different from that at diagnosis (107±26) (P> 0.05). In the 44 B-ALL patients with CD58 over-expression, FCM showed 9 MRD(+) cases and 35 MRD(-) cases, while qRT-PCR showed 11 MRD(+) cases and 33 MRD(-) cases; 42 cases (95%) showed consistent results of the two tests, so there was no significant difference between the two methods in detecting MRD (P> 0.05). Conclusions CD58 is over-expressed and stable in children with B-ALL, and it can be considered as an indicator for MRD detection in childhood B-ALL.

导出引用

李亚飞, 赵晓明, 盛光耀, 岳保红, 罗源. CD58在儿童急性B淋巴细胞白血病中的表达及其用于微小残留病检测的可行性研究[J]. 中国当代儿科杂志. 2015, 17(8): 825-829 https://doi.org/10.7499/j.issn.1008-8830.2015.08.013

LI Ya-Fei, ZHAO Xiao-Ming, SHENG Guang-Yao, YUE Bao-Hong, LUO Yuan. Expression of CD58 in childhood B-lineage acute lymphoblastic leukemia and its feasibility in minimal residual disease detection[J]. Chinese Journal of Contemporary Pediatrics. 2015, 17(8): 825-829 https://doi.org/10.7499/j.issn.1008-8830.2015.08.013

参考文献

[1] Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia[J]. J Clin Invest, 2012, 122(10): 3407-3415.
[2] Patkar N, Alex AA, Ahmed R, et al. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country[J]. Cytometry B Clin Cytom, 2012, 82(4): 252-258.
[3] Liu Q, Wang M, Hu Y, et al. Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia[J]. Leuk Lymphoma, 2014, 55(4): 892-898.
[4] Lee RV, Braylan RC, Rimsza LM. CD58 expression decreases as nonmalignant B cells mature inbone marrow and is frequently overexpressed in adult and pediatric precursor B cell acute lymphoblastic leukemia[J]. Am J Clin Pathol, 2005, 123(1): 119-124.
[5] 李彦媚, 叶铁真, 赖冬波, 等. RQ-PCR检测Ig/TCR基因重排监测急性淋巴细胞白血病患儿治疗过程微小残留白血病[J]. 中国循证儿科杂志, 2012, 7(6): 454-458.
[6] Garand R, Beldjord K, Cave H, et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL[J]. Leukemia, 2013, 27(2): 370-376.
[7] 帖利军, 顾龙军, 蒋黎敏, 等. 流式细胞技术与PCR技术联用筛选儿童急性淋巴细胞白血病微量残留标记[J]. 中国当代儿科杂志, 2009, 11(4): 246-250.
[8] Gaipa G, Basso G, Biondi A, et al. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia[J]. Cytometry B Clin Cytom, 2013, 84(6):359-369.
[9] Lutz C, Woll PS, Hall G, et al. Quiescent leukemic cells account for minimal residual disease in children lymphoblastic leukemia[J]. Leukemia, 2013, 27(5): 1204-1207.
[10] Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol, 2012, 91(2): 183-192.
[11] 张耀东, 谭利娜, 胡群, 等.儿童急性淋巴细胞白血病免疫分型特征及其临床意义[J]. 中国当代儿科杂志, 2012, 14(3): 188-191.
[12] Comerci CJ, Mace EM, Banerjee PP. CD2 promotes human natural killer cell membrane nanotube formation[J]. PLoS One, 2012, 7(10): e47664.
[13] Nina F, Lars P, Ryder, et al. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methords[J]. Haematologica, 2012, 97(1): 137-141.
[14] Thörn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry[J]. Br J Haematol, 2011, 152(6): 743-753.
[15] Denys B, van der Sluijs-Gelling AJ, Homburg C, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Leukemia, 2013, 27(3): 635-641.
[16] Ratei R, Basso G, Dworzak M, et al. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction[J]. Leukemia, 2009, 23(3): 528-534.
[17] 王丽. 儿童急性白血病微小残留病检测方法与评价[J]. 国际儿科学杂志, 2011, 38(3): 229-231.
[18] Sędek Ł, Bulsa J, Sonsala A, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?[J]. Cytometry B Clin Cytom, 2014, 86(5): 329-339.